Respiratory medicine
August 20, 2026 · via Europe PMC
Association between respiratory exacerbations and accelerated lung function decline in chronic obstructive pulmonary disease: a prospective observational population-based cohort study.
Zhou K, Wu F, Wan Q, +18 more, Ran P.
AI summary — for doctors, generated from the abstract only
In a 3-year Chinese cohort study, even mild COPD exacerbations were associated with accelerated lung function decline, including in patients with mild-to-moderate disease and low-risk GOLD A classification.
What was studied
The Early COPD (ECOPD) study, a 3-year prospective cohort study in China of 703 patients with complete annual spirometry and exacerbation data (of 915 enrolled at baseline), examining whether any mild-to-severe respiratory exacerbation, versus none, was associated with accelerated postbronchodilator FEV1 decline, including subgroup analyses in mild-to-moderate COPD and GOLD 2025 Group A.
Key findings
- Patients with any mild-to-severe exacerbation had faster postbronchodilator FEV1 decline than those without any exacerbation (adjusted difference 13 mL/year, 95% CI 3-23, P=.015).
- Patients with any exacerbation also had faster postbronchodilator FEV1% predicted decline (adjusted difference 0.5%/year, 95% CI 0.1-0.9, P=.012).
- Results were generally consistent in direction within subgroups of mild-to-moderate COPD and GOLD 2025 Group A (patients with few symptoms and no frequent exacerbations), suggesting the association held even in lower-risk patients.
Clinical relevance
The findings suggest that even mild exacerbations treated at home, not just moderate or severe exacerbations requiring outpatient or hospital care, may contribute to accelerated lung function decline in COPD, including in patients classified as lower-risk (GOLD A) or with mild-to-moderate disease, which may support considering any exacerbation, regardless of severity, in ongoing disease management and monitoring decisions.
Who should care
Limitations
This is an observational cohort study, so the association between exacerbations and faster decline cannot establish causation and may be influenced by unmeasured confounding; about 23% of the baseline cohort was excluded due to incomplete annual data, which could introduce selection effects.
Even mild COPD exacerbations were linked to faster lung function decline in this prospective cohort, including among patients with milder disease and fewer symptoms, suggesting any exacerbation may warrant clinical attention.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Background
Moderate-to-severe and severe respiratory exacerbations in chronic obstructive pulmonary disease (COPD) accelerate lung function decline. However, whether any mild-to-severe exacerbations are associated with lung function decline in COPD remains unclear, especially in mild-to-moderate COPD and in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) A.
Methods
The Early COPD (ECOPD) study was a 3-year, prospective cohort study conducted in China. Participants were diagnosed with COPD at baseline and had complete annual spirometry and exacerbation data from baseline to 3 years. Mild exacerbation was defined as an event treated domestically; moderate, treated as an outpatient; and severe, hospitalisation treatment. GOLD 2025 A was defined as COPD with few symptoms and without frequent exacerbations. Subgroup analyses were conducted in mild-to-moderate COPD and GOLD 2025 A.
Results
Of 915 participants with COPD at baseline in the ECOPD study, 703 (77%) had complete spirometry and exacerbation data each year during the 3-year follow-up and were included in the analysis. In COPD, patients with any mild-to-severe exacerbation had faster postbronchodilator forced expiratory volume in 1 s (FEV1) decline (adjusted difference 13 mL/year, 95% confidence interval [CI] 3-23, P = 0.015) and faster postbronchodilator FEV1% predicted decline (adjusted difference 0.5%/year, 95% CI 0.1-0.9, P = 0.012) than those without. Results were generally consistent in direction in mild-to-moderate COPD and GOLD 2025 A.
Conclusions
Any mild-to-severe exacerbation was associated with accelerated lung function decline in COPD, even in mild-to-moderate COPD, and this finding was generally consistent with those with GOLD 2025 A. Any exacerbation in COPD should be considered in further disease management.
DOI
10.1016/j.rmed.2026.109110
PMID
42624223
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed